Cabozantinib plus atezolizumab in non-clear cell kidney cancer
The results from an extended follow-up of the phase 1b [...]
ESMO 2022: Atezolizumab as an adjuvant therapy
The results from the IMmotion010 study were presented at the [...]
Atezolizumab plus bevacizumab does not improve survival in kidney cancer
Results from the IMmotion151 phase III clinical trial were published [...]
Cabozantinib in combination with atezolizumab for advanced kidney cancer
This phase Ib study reports the results of a combination [...]
Atezolizumab plus bevacizumab for metastatic kidney cancer patients with disease progression on atezolizumab or sunitinib
A study published in European Urology this month looks at [...]
Cabozantinib plus atezolizumab for non-clear cell kidney cancer
In this video interview, Dr Monty Pal from the City [...]
Cabozantinib plus atezolizumab combination for advanced kidney cancer
In this study, two doses of cabozantinib were tested in [...]
Immune-related adverse events from cabozantinib plus atezolizumab as first-line treatment for advanced kidney cancer
The COSMIC-021 clinical trial investigated a combination of cabozantinib and [...]
Cabozantinib plus atezolizumab for non-clear cell renal cell carcinoma
In this video interview with Dr Monty Pal from the [...]
Atexolizumab plus bevacizumab for sarcomatoid kidney cancer
A study published in European Urology in July looks at [...]
